• general@orthocell.com
  • +61 8 9360 2888
Orthocell Americas
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
  • Home
  • About
  • Team
  • Products
  • Invest
  • News
  • Practitioners
    • Striate+
    • Remplirâ„¢
    • OrthoACIâ„¢
    • Tendon
  • Contact
  • Region
    • Visit AU – Home
    • Visit Americas
    • Visit EU/UK
29 Oct 2015
Orthocell Media Permalink

Orthocell has positive tennis elbow result

Orthocell 29 October 2015

Orthocell has been featured in The Australian’s Business Spectator, following the release of new positive results from a study of our tendon cell treatment for tennis elbow. 

Read more

09 Jul 2015
Orthocell Media Permalink

Funding boost for tendon research

Orthocell 9 July 2015

The Australian has featured news of Orthocell’s Australian Research Council grant to continue its tendon research.

Read more

30 Sep 2014
Orthocell Media Permalink

Patent success a good sign for Orthocell

Orthocell 30 September 2014

Following our recent patent announcement, the Australian Financial Review has featured Orthocell in its Market Wrap.

Read more

23 Jul 2014
Orthocell Media Permalink

Strong demand for biotech

Orthocell 23 July 2014

The Australian newspaper has featured news of Orthocell’s listing on the ASX. 

Read more

10 Jun 2014
Orthocell Media Permalink

Biotech Orthocell looks to raise $8m in IPO

Orthocell 10 June 2014

Details of Orthocell’s upcoming launch on the ASX has been featured in the Australian Financial Review (AFR).

Read more

29 May 2014
Orthocell Media Permalink

Orthocell to list on ASX

Orthocell 29 May 2014

Orthocell’s plans to list on the Australian Stock Exchange (ASX) have been featured in The Australian newspaper. 

Read more

30 Jun 2011
Orthocell Media Permalink

Stem cells show promise mending busted tendons

Orthocell 30 June 2011

Jill Margo, Health Editor at the Australian Financial Review, has published a feature article on Orthocell’s innovative autologous tenocyte implantation (ATI) therapy.

Read more

  • Recent posts

    • Commercialisation of Remplirâ„¢ into US Market Continues to Build Momentum
    • Orthocell Announces Changes to its Board of Directors
    • First US Sales Revenue from Remplirâ„¢
    • OCC Quarterly Report | Quarter ended 30 June 2025
    • Orthocell Achieves a Record $2.73m in Revenue for June Quarter
Next
  • © Orthocell Ltd. All rights reserved.

  • Contact Us

  • P: +61 8 9360 2888
    F: +61 8 9360 2899
    E: general@orthocell.com

  • News Updates

  • By entering your email address you are agreeing to our privacy policy.

BUILT WITH ♡ BY H^CK Orthocell Americas POWERED BY United Themes™
Please select the country you would like to view

Visit AU – Home

Visit Americas

Visit EU/UK

Join our mailing list

    By entering your email address you are agreeing to our privacy policy.


    Sign up to our EDM

    By entering your email address you are agreeing to our privacy policy.

    Patient expression of interest